moderately severe asthma, in combination with appropriate doses of ICS, this has not been proven [5–8]. In fact, the converse has been shown – i.e. that there is an improvement in exacerbations and mortality in patients using combination therapy with ICS and LABAs [8,9].

3. “Black box warnings on the labeling for these agents [LABAs] clearly outline the increased risk for asthma-related deaths associated with their use...This information could be used to reassess whether these agents should be withdrawn from the market.” The SMART study [1] has provoked questions internationally and has made us review our use of LABAs. At a recent update meeting of the Canadian Consensus guideline group, combination therapy (LABA plus ICS in one device) was recommended as a means to decrease the use of LABAs as monotherapy in asthma. Further confusion arises when studies using LABA alone (without ICS) are reported on subjects with asthma and COPD [10]. Monotherapy with LABAs is acceptable in COPD [11] but is unsafe in patients with asthma [1].

It is premature (and inappropriate) of the authors of this paper to suggest that withdrawal of LABAs should even be considered. LABAs have proven efficacy and safety if used in addition to ICS for patients with asthma.

References

- [1] Nelson HS, Weiss ST, Bleecker ER, et al., SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129(1):15–26.
- [2] Summary of recommendations of Canadian Adult and Pediatric Consensus Asthma Guidelines CMAJ 2005;173(6 suppl):S1–S56.
- [3] Global Strategy for Asthma Management and Prevention NIH Publication No 02-3659 Issued January 1995, (Updated 2004).
- [4] British Guideline on the Management of Asthma. BTS/SIGN. *Thorax* 2003;58(Suppl 1).
- [5] Bateman ED, Boushey HA, Bousquet J, et al., GOAL Investigators Group. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. *Am J Respir Crit Care Med* 2004;170(8):836–44.
- [6] O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. *Am J Respir Crit Care Med* 2001;164(8 Pt 1):1392–7.
- [7] O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. *Am J Respir Crit Care Med* 2005;171(2):129–36.
- [8] Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N Engl J Med* 1997;337(20):1405–11.
- [9] Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing corticosteroid. *Lancet* 1997;334:219–24.
- [10] Kaplan A. Chronic Obstructive Pulmonary Disease. Family Physician’s role in management. *Canadian Family Physician* 2004;750–5.
- [11] O’Donnell Aaron SP, Bourbeau JD, Henrnadez, Marciniuk D, Balter M, et al. Canadian Thoracic Society recommendations for management of COPD. *Can Respir J* 2003;10(Suppl A):11A–65A.

doi:10.1016/j.pcrj.2006.08.002

Review of “Pharmacological strategies of self management of asthma exacerbations.” Reddel H, Barnes D, on behalf of Exacerbation Advisory Panel. *Eur Resp J* 2006; 28: 182–199.

Justin Beilby*

Executive Dean, University of Adelaide

*Tel.: +61 8 8303 5193.

E-mail address: justin.beilby@adelaide.edu.au.

Commentary

This is a useful review with a number of sensible aims. These were:

1. To determine the efficacy of using oral corticosteroids (OCS) in adults experiencing an asthma exacerbation, alone or in combination with combination therapy.
2. To determine the efficacy of using inhaled corticosteroids (ICS) in patients with asthma experiencing an exacerbation, alone or in combination with combination therapy.
3. To determine the efficacy of increasing the dose of combination therapy in adults experiencing an exacerbation, currently receiving combination therapy.
4. To determine the efficacy of using short acting B-agonists (SABA) in patients experiencing an exacerbation, both in general and in particular whilst receiving combination therapy.

Complicating the analyses was the fact that there was wide variation in the definition of an exacerbation. However, there are some important findings for primary care here. The studies chosen for the review, identified from a Medline search from 1990–2004, were taken from hospital settings (8 in total), Emergency Departments (ED) (11) and community settings (14). The authors made an

important point that the ED and hospital studies are not directly applicable to self management by patients with written action plans, a model that is currently being emphasised in primary care.

The role of OCS and SABAs in the management of exacerbations was reaffirmed and the lack of value of just doubling the dose of ICS was emphasised. When the role of high doses of inhaled steroids was examined, there was clear evidence that increases to daily dose of 2000 micrograms of fluticasone or 3,200 micrograms of budesonide or equivalent for a period of 7–14 days was acceptable and efficacious in treating exacerbations.

The most useful information for general practitioners was the summary of the evidence regarding the management of patients who are using combination therapy. Six studies have examined the role of a two- to four-fold increase in budesonide/formoterol in managing exacerbations: two showed a reduction and four studies were inconclusive. The authors argued that no definite recommendations can be made at this time. The continuing role of SABAs for relief of exacerbations in patients with combination therapy was re-emphasised and it was suggested that a higher dose may be required, due to the fact that LABAs are associated with some bronchodilator subsensitivity.

Future research includes the need for more community-based studies to refine our understanding of the correct therapeutic interventions for different levels of exacerbations – mild to moderate vs severe – and among adults and children. We still need more specific information within written action plans in self management education.

doi:10.1016/j.pcrj.2006.08.003

Review of "Asthma—At your fingertips." Mark Levy, Trisha Weller, and Sean Hilton
Fourth Edition, 2006 Class Publishing, Barb House, Barb Mews, London W6 7PA, Full price £20.99, Internet prices around £11.60

Steve Holmes*

GPIAG General Committee Chairman, The Park Medical Practice, Shepton Mallet, Somerset, UK

*Tel.: +44 1749 334383; fax: +44 1749 334393.

E-mail address: steve.holmes@btinternet.com.

This book, written for patients, is now in its fourth edition. First published in 1993, and with significant changes in practice and care since, it is important to ask whether or not the book has adapted to match these changes. Perhaps the fact that it is now in its fourth edition indicates that it has indeed.

Will the book be suitable for all the 5.2 million people estimated to have asthma in the UK? This review is based on patients' and clinical colleagues' comments on previous editions, as well as a selective view of whether or not it is current, authoritative, evidence-based and addresses patient concerns.

At 300 pages long this book will not suit every patient or carer as a 'must read' as soon as a diagnosis of asthma is made, but it will address the common concerns that patients and carers ask us – and it does this in detail. It would be a great resource in every health care library (hospital and primary care) as well as in local public libraries. Certainly, in many practices, copies have been lent out. I know many primary healthcare professionals who use this book to find information to answer patients' queries rather than using some of the harder-to-access and less understandable professional tomes.

Using this book is easy. There is a good index and content pages – there are details of all the inhaler devices currently available, and there are references to internet sites of interest. There is sufficient detail to answer most questions comprehensively and it is good that the book has adapted to recent changes such as the new British Guidelines on asthma management, and that it has encapsulated currently accepted views well. The main controversial areas of complementary health care are carefully dealt with in a sensible and open fashion.

My colleagues and patients often borrow practice library copies and are highly complimentary. This is fully justified. Just a word of warning; expect professionals to use the book as a reference, and expect patients to forget to return the book as it is a useful resource at home. Be prepared to buy more than one copy if you want to keep a copy for yourself. The other option is to keep it under lock and key...

doi:10.1016/j.pcrj.2006.08.004

Available online at www.sciencedirect.com

ScienceDirect

Available online at <http://www.thepcrj.com>